The Biden administration plans to reduce expenses for 64 medications by imposing inflation penalties on pharmaceutical companies.

• Medicare-enrolled older Americans will see lower prescription drug costs in the third quarter of this year, as the Biden administration imposes inflation penalties on 64 drugs.
• Lowering U.S. drug prices is a crucial element of President Joe Biden's health-care strategy for both his current term and his potential reelection in 2024.
• Medicare will receive rebates from drugmakers if they increase the price of medication at a faster rate than inflation, as per a provision in Biden's Inflation Reduction Act.

Medicare beneficiaries will see lower prescription drug costs in the third quarter of this year, as the Biden administration announced inflation penalties on 64 drugs.

Medicare will receive rebates from drugmakers if they increase the price of medication faster than inflation, as per a provision in President Joe Biden's Inflation Reduction Act, which is a key component of his health-care agenda and reelection platform for 2024.

Medicare has the authority to negotiate lower prescription drug prices with manufacturers, but Americans still pay significantly more for prescription drugs than patients in other developed countries, according to the Biden administration.

Medicare Part B will cover 64 drugs at a lower coinsurance rate for patients from July 1 to Sept. 30, as each drug company raised prices faster than the rate of inflation, according to a release from the administration.

Medicare Part B patients could potentially save up to $4,593 per day by utilizing certain drugs during the quarter, according to the release.

Medicare patients use drugs to treat conditions such as cancer, certain infections, and osteoporosis, with over 750,000 patients utilizing these medications annually, according to a release.

The list comprises Abecma, a cell therapy for multiple myeloma, Adectris, a targeted cancer treatment for specific lymphomas, and Padcev, a targeted cancer treatment for advanced bladder cancer, developed by Astellas Pharma and Pfizer.

Since the Medicare inflation rebate program was implemented, the price of Padcev has risen at a faster rate than inflation in every quarter.

Seniors were vulnerable to Big Pharma's price increases without the Inflation Reduction Act, but that has changed, according to Neera Tanden, White House domestic policy advisor.

In 2025, the Centers for Medicare & Medicaid Services will issue the first invoices to pharmaceutical companies for the rebates that are due to the program.

During the first quarter of 2024, 48 prescription drugs will face inflation penalties, as announced by Biden in December.